Memorial Sloan Kettering Cancer Center
- Country
- πΊπΈUnited States
- Ownership
- Private
- Established
- 1884-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.mskcc.org
Acute Changes in Endothelial Function in Germ Cell Tumor Patients Treated With Cisplatin and Untreated Germ Cell Tumor Controls
- Conditions
- Germ Cell Cancer
- Interventions
- Other: Endo-PAT2000 testing
- First Posted Date
- 2011-10-18
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 44
- Registration Number
- NCT01453660
- Locations
- πΊπΈ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)
- Conditions
- Lung Cancer
- Interventions
- First Posted Date
- 2011-09-29
- Last Posted Date
- 2018-08-09
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 42
- Registration Number
- NCT01443078
- Locations
- πΊπΈ
Memorial Sloan-Kettering at Mercy Medical Center, Rockville Centre, New York, United States
πΊπΈMemorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center, Sleepy Hollow, New York, United States
πΊπΈMemoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
Acute Normovolemic Hemodilution in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian Cancer
- Conditions
- Primary Peritoneal CarcinomaEpithelial Ovarian CancerFallopian Tube Cancer
- Interventions
- Procedure: Acute Normovolemic Hemodilution
- First Posted Date
- 2011-09-28
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 52
- Registration Number
- NCT01442051
- Locations
- πΊπΈ
Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
πΊπΈMemorial Sloan Kettering Cancer Center, New York, New York, United States
πΊπΈMemorial Sloan Kettering West Harrison, Harrison, New York, United States
Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant
- Conditions
- Mantle Cell Lymphoma
- Interventions
- Biological: Ofatumumab (This arm is closed)Other: Ofatumumab + Bendamustine
- First Posted Date
- 2011-09-21
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT01437709
- Locations
- πΊπΈ
Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge, New Jersey, United States
πΊπΈMemorial Sloan Kettering West Harrison, Harrison, New York, United States
πΊπΈMemorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States
Spanish Translation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
- Conditions
- Cancer
- Interventions
- Behavioral: questionnaire administration followed by cognitive interviews
- First Posted Date
- 2011-09-19
- Last Posted Date
- 2017-05-23
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 112
- Registration Number
- NCT01436240
- Locations
- πΊπΈ
University of Miami, Miami, Florida, United States
πΊπΈMd Anderson Cancer Center, Houston, Texas, United States
πΊπΈRalph Lauren Center for Cancer Care and Prevention, New York, New York, United States
In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies
- Conditions
- Acute Lymphocytic LeukemiaLymphoma
- Interventions
- Biological: Biological/Genetically Modified T cellsDrug: Cyclophosphamide-based chemotherapy
- First Posted Date
- 2011-09-08
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 19
- Registration Number
- NCT01430390
- Locations
- πΊπΈ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases
- Conditions
- Gastro-enteropancreatic Neuroendocrine TumorSecondary Malignant Neoplasm of Liver
- Interventions
- Other: magnetic resonance imaging (MRI)
- First Posted Date
- 2011-08-26
- Last Posted Date
- 2023-01-23
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT01423734
- Locations
- πΊπΈ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors
- Conditions
- Neuroblastoma
- Interventions
- Biological: Humanized 3F8 Monoclonal Antibody (Hu3F8)
- First Posted Date
- 2011-08-18
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 68
- Registration Number
- NCT01419834
- Locations
- πΊπΈ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)
- Conditions
- LeiomyosarcomaMalignant Peripheral Nerve Sheath TumorHistiocytoma/Undifferentiated Pleomorphic SarcomaSarcomaMalignant Fibrous
- Interventions
- First Posted Date
- 2011-08-16
- Last Posted Date
- 2018-01-11
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 5
- Registration Number
- NCT01418001
- Locations
- πΊπΈ
Washington University School of Medicine, Saint Louis, Missouri, United States
πΊπΈMemorial Sloan-Kettering Cancer Center, New York, New York, United States
πΊπΈUCLA, Los Angeles, California, United States
Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab
- First Posted Date
- 2011-08-15
- Last Posted Date
- 2019-01-11
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 13
- Registration Number
- NCT01416974
- Locations
- πΊπΈ
Memorial Sloan Kettering Cancer Center, New York, New York, United States